Lv3
202 积分 2022-05-28 加入
Antibody–drug conjugates come of age in oncology
1天前
已完结
抗体药物偶联物治疗恶性肿瘤临床应用中国专家共识(2023版)
1天前
已完结
抗体偶联药物安全性跨学科管理中国专家共识(2023)
1天前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
3个月前
已完结
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
3个月前
已完结
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
3个月前
已完结
Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
3个月前
已完结
Evolution of claudin18.2 therapies in gastroesophageal cancers
4个月前
已完结
皖公网安备34019202002308
